Unilever and FF&P exit BAC BV

The acquisition will expand Life Technologies' capabilities and product offering in biopharmaceutical research and manufacturing.

The financial terms remain undisclosed, but the sale was described as profitable.

Previous funding
Unilever first backed the firm in 2002, supporting its spinout from the Unilever Vlaardingen R&D facility in the Netherlands. In 2005, the GP joined FF&P in a series-A investment round for the company. In 2008, a consortium of existing investors led by Unilever and FF&P backed BAC with €1.5m.

Company
Founded in 1995 in Naarden, BAC BV began as a biotech development facility. In 2002, Unilever Ventures supported the management's plan to turn to antibody engineering and manufacture, establishing a commercial operation to develop and market products for biopharmaceutical purification.

The firm has developed a technology platform that comprises purification and affinity separation products used for the discovery, pre-clinical and clinical manufacture of therapeutic proteins, including antibodies and antibody fragments. Its products reduce the time to market, increase purity and yield, and lower the cost of goods for drug development.

People
Andrew Lane is a director at Unilever and previously sat on the board of BAC. Dan Walker is an investment director at FF&P and a board director of BAC.

Advisers
Vendors - Clearwater, Philip Nuttall, Ramesh Jassal, Nick Horrocks (Corporate finance).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Benelux
• Healthcare
• Exits
• Netherlands
• FF&P Private Equity